Want to see SG:9G2 full AI Analyst Report?
9G2 Stock Chart & Stats
S$0.07
S$0.00(0.00%)
At close: 4:00 PM EST
S$0.07
S$0.00(0.00%)
Day’s Range― - ―
52-Week RangeS$0.02 - S$0.08
Previous CloseN/A
Volume159.90K
Average Volume (3M)247.96K
Market Cap
S$43.10M
Enterprise ValueS$100.88M
Total Cash (Recent Filing)S$2.48M
Total Debt (Recent Filing)S$58.62M
Price to Earnings (P/E)―
Beta-0.21
Next Earnings
Nov 03, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.02
Shares Outstanding1,724,092,500
10 Day Avg. Volume138,640
30 Day Avg. Volume247,960
Financial Highlights & Ratios
PEG Ratio0.04
Price to Book (P/B)0.55
Price to Sales (P/S)1.94
P/FCF Ratio-2.83
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Strong Revenue Scaling (2025)Sharp ~95% revenue growth in 2025 indicates expanding demand and greater market traction. Sustained top-line expansion supports absorption of fixed costs, improves operating leverage potential, and creates a clearer route to profitability if growth and margin trends continue over the medium term.
Very High Gross Margins (~92%)Sustained ~92% gross margins point to strong pricing power or a low-variable-cost service model. High structural gross profit provides headroom to cover SG&A and investment, making the business more able to achieve operating profitability as revenue scales and fixed costs are spread.
Material FCF Improvement In 2025A ~91% year-over-year improvement in free cash flow, even from negative levels, signals better cash conversion and operational control. If this trend persists, it reduces reliance on external funding, lowers execution risk, and supports more sustainable operations over the medium term.
Bears Say
Deep, Persistent Net LossesNet margins of roughly -167% in 2025 (and -225% in 2024) reflect structural unprofitability. Such deep losses mean core operations do not yet cover total costs; absent sustained revenue growth and operating-cost control, the company faces prolonged funding needs and uncertain path to normalized profits.
Consistent Negative Operating Cash FlowRecurring negative operating cash flow (-10.6M in 2025) indicates ongoing cash burn from operations. Persistent OCF deficits require ongoing external financing or asset/liability adjustments, increasing dilution or leverage risk and constraining the company's ability to invest or withstand downturns over the medium term.
Elevated And Rising LeverageDebt-to-equity rebounding to ~1.05 and historically higher levels reduce financial flexibility and increase interest and refinancing risk. With negative earnings and cash flow, elevated leverage amplifies funding vulnerability and limits capacity to fund growth or absorb shocks without dilutive or costly financing.
Singapore Institute of Advanced Medicine Holdings Ltd. News
9G2 FAQ
What was Singapore Institute of Advanced Medicine Holdings Ltd.’s price range in the past 12 months?
Singapore Institute of Advanced Medicine Holdings Ltd. lowest share price was S$0.02 and its highest was S$0.08 in the past 12 months.
What is Singapore Institute of Advanced Medicine Holdings Ltd.’s market cap?
Singapore Institute of Advanced Medicine Holdings Ltd.’s market cap is S$43.10M.
When is Singapore Institute of Advanced Medicine Holdings Ltd.’s upcoming earnings report date?
Singapore Institute of Advanced Medicine Holdings Ltd.’s upcoming earnings report date is Nov 03, 2026 which is in 115 days.
How were Singapore Institute of Advanced Medicine Holdings Ltd.’s earnings last quarter?
Singapore Institute of Advanced Medicine Holdings Ltd. released its earnings results on May 14, 2026. The company reported -S$0.004 earnings per share for the quarter, missing the consensus estimate of N/A by -S$0.004.
Is Singapore Institute of Advanced Medicine Holdings Ltd. overvalued?
According to Wall Street analysts Singapore Institute of Advanced Medicine Holdings Ltd.’s price is currently Overvalued.
Does Singapore Institute of Advanced Medicine Holdings Ltd. pay dividends?
Singapore Institute of Advanced Medicine Holdings Ltd. does not currently pay dividends.
What is Singapore Institute of Advanced Medicine Holdings Ltd.’s EPS estimate?
Singapore Institute of Advanced Medicine Holdings Ltd.’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Singapore Institute of Advanced Medicine Holdings Ltd. have?
Singapore Institute of Advanced Medicine Holdings Ltd. has 1,724,092,500 shares outstanding.
What happened to Singapore Institute of Advanced Medicine Holdings Ltd.’s price movement after its last earnings report?
Singapore Institute of Advanced Medicine Holdings Ltd. reported an EPS of -S$0.004 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went down -6.522%.
Which hedge fund is a major shareholder of Singapore Institute of Advanced Medicine Holdings Ltd.?
Currently, no hedge funds are holding shares in SG:9G2
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Singapore Institute of Advanced Medicine Holdings Ltd. Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Technicals
SMA
Negative
20 days / 200 days
Momentum
-55.69%
12-Months-Change
Fundamentals
Return on Equity
-79.37%
Trailing 12-Months
Asset Growth
-7.63%
Trailing 12-Months
Company Description
Singapore Institute of Advanced Medicine Holdings Ltd.
Singapore Institute of Advanced Medicine Holdings Ltd. operates as a holding company primarily focused on delivering healthcare services. Its operations include providing pharmaceutical products, surgical supplies, and medical laboratory services. The company was founded by Djeng Shih Kien on November 24, 2011, and is headquartered in Singapore.
Singapore Institute of Advanced Medicine Holdings Ltd. (9G2) Earnings & Revenues
Technical Analysis
Raffles Medical Group
―
Thomson Medical Group Ltd.
―
HC Surgical Specialists Ltd
―
ISEC Healthcare Ltd
―
OUE Lippo Healthcare Limited
―
Options Prices
Currently, No data available
---